Misonix (MSON) 10-K 20 Aug 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2015	Aug. 20, 2015	Dec. 31, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	MISONIX INC
Entity Central Index Key	880,432
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 81,749,310
Trading Symbol	MSON
Entity Common Stock, Shares Outstanding		7,744,113

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current assets:
Cash and cash equivalents	$ 9,623,749	$ 7,039,938
Accounts receivable, less allowance for doubtful accounts of $126,868 and $136,868, respectively	4,481,247	3,759,152
Inventories, net	4,303,163	4,217,350
Prepaid expenses and other current assets	441,562	367,830
Deferred income tax - current	2,118,716	0
Total current assets	20,968,437	15,384,270
Property, plant and equipment, net of accumulated amortization and depreciation of $5,672,287 and $4,842,009, respectively	2,056,600	1,517,852
Goodwill	1,701,094	1,701,094
Intangible and other assets	954,405	924,653
Deferred income tax - long term	773,712	0
Total assets	26,454,248	19,527,869
Current liabilities:
Accounts payable	1,147,414	1,650,323
Accrued expenses and other current liabilities	1,532,094	1,457,250
Total current liabilities	2,679,508	3,107,573
Deferred lease liability	0	16,614
Deferred income	20,395	51,318
Total liabilities	$ 2,699,903	$ 3,175,505
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $.01 par value-shares authorized 20,000,000, 7,869,095 and 7,412,096 shares issued and 7,744,113 and 7,334,536 shares outstanding, respectively	$ 78,691	$ 74,121
Additional paid-in capital	30,531,129	28,169,622
Accumulated deficit	(5,909,215)	(11,480,386)
Treasury stock, at cost, 124,982 and 77,560 shares, respectively	(946,260)	(410,993)
Total stockholders' equity	23,754,345	16,352,364
Total liabilities and stockholders' equity	$ 26,454,248	$ 19,527,869

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Allowance for doubtful accounts (in dollars)	$ 126,868	$ 136,868
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars)	$ 5,672,287	$ 4,842,009
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	7,869,095	7,412,096
Common stock, shares outstanding	7,744,113	7,334,536
Treasury stock, shares	124,982	77,560

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Net sales	$ 22,204,578	$ 17,060,435	$ 14,827,226
Cost of goods sold	7,280,276	5,933,867	7,427,247
Gross profit	14,924,302	11,126,568	7,399,979
Operating expenses:
Selling expenses	9,062,695	7,272,726	6,776,204
General and administrative expenses	5,983,623	4,691,055	4,446,489
Research and development expenses	1,592,923	1,711,751	1,496,058
Total operating expenses	16,639,241	13,675,532	12,718,751
Loss from operations	(1,714,939)	(2,548,964)	(5,318,772)
Other income (expense):
Interest income	75	69	75
Interest expense	0	0	(7)
Royalty income and license fees	4,256,321	3,725,436	2,511,655
Royalty expense	0	0	(13,361)
Other	(22,033)	(19,331)	(101,533)
Total other income	4,234,363	3,706,174	2,396,829
Income/(loss) from continuing operations before income taxes	2,519,424	1,157,210	(2,921,943)
Income tax (benefit)/expense	(2,784,632)	30,630	(75,196)
Net income/(loss) from continuing operations	5,304,056	1,126,580	(2,846,747)
Discontinued operations:
Income from discontinued operations net of tax expense of $1,127, $235 and $1,853, respectively	17,115	19,666	3,596
Gain from sale of discontinued operations net of tax expense of $0, $2,947 and $77,814, respectively	250,000	247,053	172,186
Net income from discontinued operations	267,115	266,719	175,782
Net income/(loss)	$ 5,571,171	$ 1,393,299	$ (2,670,965)
Net income/(loss) per share from continuing operations - Basic (in dollars per share)	$ 0.70	$ 0.15	$ (0.40)
Net income per share from discontinued operations - Basic (in dollars per share)	0.04	0.04	0.02
Net income/(loss) per share - Basic (in dollars per share)	0.74	0.19	(0.38)
Net income/(loss) per share from continuing operations - Diluted (in dollars per share)	0.66	0.15	(0.40)
Net income per share from discontinued operations - Diluted (in dollars per share)	0.03	0.04	0.02
Net income/(loss) per share - Diluted (in dollars per share)	$ 0.69	$ 0.19	$ (0.38)
Weighted average shares - Basic (in shares)	7,580,450	7,232,004	7,050,423
Weighted average shares - Diluted (in shares)	8,094,119	7,467,592	7,050,423

Consolidated Statements of Ope5

Consolidated Statements of Operations [Parenthetical] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income from discontinued operations, Tax expense	$ 1,127	$ 235	$ 1,853
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	$ 2,947	$ 77,814

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2012	$ 15,590,067	$ 70,829	$ (410,993)	$ 26,132,951	$ (10,202,720)
Balance (in shares) at Jun. 30, 2012		7,082,920	(77,560)
Net income/comprehensive income	(2,670,965)	$ 0	$ 0	0	(2,670,965)
Proceeds from exercise of stock options	369,646	$ 1,510	$ 0	368,136	0
Proceeds from exercise of stock options (in shares)		150,964	0
Stock-based compensation	488,472	$ 0	$ 0	488,472	0
Balance at Jun. 30, 2013	13,777,220	$ 72,339	$ (410,993)	26,989,559	(12,873,685)
Balance (in shares) at Jun. 30, 2013		7,233,884	(77,560)
Net income/comprehensive income	1,393,299	$ 0	$ 0	0	1,393,299
Proceeds from exercise of stock options	484,960	$ 1,782	$ 0	483,178	0
Proceeds from exercise of stock options (in shares)		178,212	0
Stock-based compensation	696,885	$ 0	$ 0	696,885	0
Balance at Jun. 30, 2014	16,352,364	$ 74,121	$ (410,993)	28,169,622	(11,480,386)
Balance (in shares) at Jun. 30, 2014		7,412,096	(77,560)
Net income/comprehensive income	5,571,171	$ 0	$ 0	0	5,571,171
Proceeds from exercise of stock options	723,560	$ 4,570	$ (535,267)	1,254,257	0
Proceeds from exercise of stock options (in shares)		456,999	(47,422)
Stock-based compensation	1,107,250	$ 0	$ 0	1,107,250	0
Balance at Jun. 30, 2015	$ 23,754,345	$ 78,691	$ (946,260)	$ 30,531,129	$ (5,909,215)
Balance (in shares) at Jun. 30, 2015		7,869,095	(124,982)

Consolidated Statement of Stoc7

Consolidated Statement of Stockholders' Equity [Parenthetical] - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Common Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Operating activities
Net income/(loss) from continuing operations	$ 5,304,056	$ 1,126,580	$ (2,846,747)
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) by continuing operating activities:
Depreciation and amortization and other non-cash items	1,439,972	978,468	785,437
Bad debt (recovery)/expense	(10,000)	(77,773)	58,902
Deferred income tax benefit	(2,892,428)	0	0
Stock-based compensation	1,107,250	696,885	488,472
Deferred income	(46,052)	(17,786)	(36,216)
Deferred lease liability	(16,614)	(7,197)	815
Changes in operating assets and liabilities:
Accounts receivable	(712,095)	(706,738)	124,541
Inventories	(1,259,986)	(1,033,624)	92,926
Prepaid expenses and other assets	(129,828)	106,741	40,488
Accounts payable, accrued expenses and other non-cash items	(412,936)	(382,219)	895,337
Net cash provided by/(used in) continuing operating activities	2,371,339	683,337	(396,045)
Investing activities
Acquisition of property, plant and equipment	(345,312)	(72,437)	(533,239)
Payments for assets acquisition	(328,136)	0	0
Additional patents	(104,755)	(129,078)	(82,722)
Net cash used in investing activities	(778,203)	(201,515)	(615,961)
Financing activities
Proceeds from exercise of stock options	723,560	484,960	369,646
Net cash provided by financing activities	723,560	484,960	369,646
Cash flows from discontinued operations
Net cash provided by/(used in) operating activities	17,115	16,719	(74,218)
Net cash provided by investing activities	250,000	250,000	250,000
Net cash provided by discontinued operations	267,115	266,719	175,782
Net increase/(decrease) in cash and cash equivalents	2,583,811	1,233,501	(466,578)
Cash and cash equivalents at beginning of period	7,039,938	5,806,437	6,273,015
Cash and cash equivalents at end of period	9,623,749	7,039,938	5,806,437
Supplemental disclosure of cash flow information:
Cash paid for Interest	0	0	7
Cash paid for Income taxes	$ 86,070	$ 26,954	$ 32,341

Basis of Presentation, Organiza

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	The consolidated financial statements of MISONIX, INC. (“Misonix” or the “Company”) include the accounts of Misonix and its 100 Misonix is a surgical device company, operating in one business segment, that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications. The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made through distributors. Sales made in the United States are made primarily through representative agents. For the years ended June 30, 2015 2014 United States $ 10,797,920 $ 8,185,468 Australia 364,156 120,118 Europe 3,385,603 2,387,376 Asia 4,125,662 3,572,056 Canada and Mexico 836,188 779,833 South America 911,711 1,165,124 South Africa 540,185 378,287 Middle East 1,243,153 472,173 $ 22,204,578 $ 17,060,435 For the years ended June 30, 2014 2013 United States $ 8,185,468 $ 7,649,041 Australia 120,118 358,509 Europe 2,387,376 3,062,307 Asia 3,572,056 1,619,255 Canada and Mexico 779,833 516,088 South America 1,165,124 735,060 South Africa 378,287 489,756 Middle East 472,173 397,210 $ 17,060,435 $ 14,827,226 For the years ended June 30, 2015 2014 2013 Revenues $ 18,242 $ 19,901 $ 19,901 Income from discontinued operations, before tax $ 18,242 $ 19,901 $ 5,449 Gain on sale of discontinued operations 250,000 250,000 250,000 Income tax benefit/(expense) (1,127) (3,182) (79,667) Net income from discontinued operations, net of tax $ 267,115 $ 266,719 $ 175,782 High Intensity Focused Ultrasound Technology In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to SonaCare Medical (“SonaCare”), Misonix will receive up to approximately $ 5.8 7 3 5 5.8 Commencing 90 days after each December 31st and beginning December 31, 2011 the payments due to Misonix will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million 1,004,788 The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions. At June 30, 2015, these financial institutions held cash that was approximately $ 9,375,735 Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $ 2,974,086 2,495,960 619,537 3,820 5,226 110,437 497,581 636,085 1,425,708 4,162,000 3,619,000 2,369,000 1,012,000 892,000 1,000 121,000 586,000 606,000 1,805,000 1,332,000 Accounts receivable, principally trade, are generally due within 30 90 Inventories are stated at the lower of cost (first-in, first-out) or market and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or market on a quarterly basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. During the year ended June 30, 2013 the Company also established inventory reserves aggregating approximately $ 835,000 Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years. See Note 4. The Company records revenue upon shipment for products shipped F.O.B. shipping point. Products shipped F.O.B. destination points are recorded as revenue when received at the point of destination. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from exclusive license agreements are recognized ratably over the terms of the respective agreements. Service contracts and royalty income are recognized when earned. The Company presents taxes collected from customers and remitted to governmental authorities in the consolidated statements of operations on a net basis. The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, an historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2015, 2014 or 2013. Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. We primarily utilize a discontinued cashflow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2015 and 2014 as of June 30th each year. No impairment of goodwill was deemed to exist in fiscal 2015, 2014 or 2013. The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $ 566,028 611,355 791,551 641,469 150,000 83,000 75,000 Net customer relationships are amortized over 5 years and reported in intangible and other assets and totaled $ 40,000 200,000 760,000 600,000 160,000 Net reacquired contractual rights from Aesculap reported in intangible and other assets totaled $ 178,983 0 149,153 0 149,153 0 0 Customer Reacquired Patents Relationships Contractual Rights 2016 $ 85,636 $ 40,000 $ 178,983 2017 80,540 - - 2018 77,960 - - 2019 70,353 - - 2020 47,425 - - Thereafter 204,114 - - $ 566,028 $ 40,000 $ 178,983 Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense. Basic income (loss) per common share ("Basic EPS") is computed by dividing income (loss) by the weighted average number of common shares outstanding using the treasury stock method. Diluted income (loss) per common share ("Diluted EPS") is computed by dividing income (loss) by the weighted average number of common shares and the dilutive common share equivalents and convertible securities then outstanding. For the years ended June 30, 2015 2014 2013 Basic shares 7,580,450 7,232,004 7,050,423 Dilutive effect of stock options 513,669 235,588 - Diluted shares 8,094,119 7,467,592 7,050,423 Excluded from the calculation to Diluted EPS are options to purchase 257,000 312,630 1,729,991 Total comprehensive income/(loss) was $ 5,571,171 1,393,299 2,670,965 All research and development expenses are expensed as incurred and are included in operating expenses. The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $ 155,000 100,000 141,000 The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and stock-based compensation. Actual results could differ from those estimates. Shipping and handling fees for the fiscal years ended June 30, 2015, 2014 and 2013 were approximately $ 62,000 75,000 47,000 87,000 85,000 101,000 The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms. In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-08, “Presentation of Financial Statements (Topic 205)” and “Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” The amendments in the ASU change the criteria for reporting discontinued operations while enhancing related disclosures. The amendments in the ASU are effective in the first quarter of 2015. The adoption of ASU 2014-08 did not have a material impact on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. This pronouncement has been officially deferred for one year. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	2. Fair Value of Financial Instruments We follow a three-level fair value hierarchy that prioritizes the inputs to measure fair value. This hierarchy requires entities to maximize the use of "observable inputs" and minimize the use of "unobservable inputs." The three levels of inputs used to measure fair value are as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect assumptions that market participants would use in pricing an asset or liability. The following is a summary of the carrying amounts and estimated fair values of our financial instruments: June 30, 2015 June 30, 2014 Carrying Fair Carrying Fair Amount Value Amount Value Cash and cash equivalents $ 9,623,749 $ 9,623,749 $ 7,039,938 $ 7,039,938 Trade accounts receivable 4,481,247 4,481,247 3,759,152 3,759,152 Trade accounts payable 1,147,414 1,147,414 1,650,323 1,650,323 The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and Cash Equivalents The carrying amount approximates fair value because of the short maturity of those instruments. Trade Accounts Receivable The carrying amount of trade receivables reflects net recovery value and approximates fair value because of their short outstanding terms. Trade Accounts Payable The carrying amount of trade payables approximates fair value because of their short outstanding terms.

Inventories

Inventories	12 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	3. Inventories Inventories are summarized as follows: June 30, June 30, 2015 2014 Raw material $ 2,096,443 $ 1,820,046 Work-in-process 660,267 410,827 Finished goods 2,536,699 3,337,568 5,293,409 5,568,441 Less valuation reserve 990,246 1,351,091 $ 4,303,163 $ 4,217,350

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property, Plant and Equipment June 30, June 30, 2015 2014 Machinery and equipment $ 1,998,574 $ 1,887,309 Furniture and fixtures 1,287,070 1,234,104 Automobiles 22,328 22,328 Leasehold improvements 476,501 445,879 Demonstration and consignment inventory 3,944,414 2,770,241 7,728,887 6,359,861 Less: accumulated depreciation and amortization (5,672,287) (4,842,009) $ 2,056,600 $ 1,517,852 Depreciation and amortization of property, plant and equipment totaled approximately $ 981,000 732,000 550,000

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. Accrued Expenses and Other Current Liabilities June 30, June 30, 2015 2014 Accrued payroll and vacation $ 507,172 $ 460,341 Accrued bonuses 300,000 250,000 Accrued commissions 321,440 340,462 Accrued professional and legal fees 97,880 85,832 Income tax payable 71,302 29,506 Deferred income 40,911 102,453 Other $ 193,389 $ 188,656 $ 1,532,094 $ 1,457,250

Leases

Leases	12 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	6. Leases Misonix has entered into several noncancellable operating leases for the rental of certain manufacturing and office space, equipment and automobiles expiring in various years through 2019. The principal building lease provides for a monthly rental of approximately $ 26,000 Operating Leases 2016 $ 347,038 2017 343,580 2018 331,847 Total minimum lease payments $ 1,022,465 Certain of the leases provide for escalation clauses, renewal options and the payment of real estate taxes and other occupancy costs. Rent expense for all operating leases was approximately $ 375,000 392,000 387,000

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Stock-Based Compensation Plans Stock options are granted with exercise prices not less than the fair market value of our common stock, par value $ .01 549,000 324,000 357,000 Compensation expense is recognized in the general and administrative expenses line item of the Company's consolidated statements of operations on a straight-line basis over the vesting periods. There are no capitalized stock-based compensation costs at June 30, 2015 and 2014. As of June 30, 2015, there was approximately $ 3,583,000 2.8 Shares may be acquired by various methods. They may be acquired by (a) cash or by certified check, (b) with previously acquired shares of Common Stock having an aggregate fair market value, on the date of exercise, equal to the aggregate exercise price of all options being exercised (provided that such shares were not acquired less than six (6) months prior to such exercise date), (c) by surrendering options to acquire shares of Common Stock in exchange for the number of shares of Common Stock equal to the product of the number of shares of Common Stock as to which the option is being exercised multiplied by a fraction, the numerator of which is the fair market value of the Common Stock less the exercise price of the options and the denominator of which is such fair market value. Cash in the amount of $ 723,560 47,422 579,463 47,250 28,000 The weighted average fair value at date of grant for options granted during the fiscal years ended June 30, 2015, 2014 and 2013 was $ 5.70 3.95 3.04 2015 2014 2013 Risk-free interest rates 1.6 % 3.0 % 2.5 % Expected option life in years 6.5 6.5 6.5 Expected stock price volatility 61.13 % 76.09 % 75.15 % Expected dividend yield 0 % 0 % 0 % The risk free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The expected option term is based upon the number of years the Company estimates the option will be outstanding based on historical exercises and terminations. The expected dividend yield is based upon historical and projected dividends. The Company estimates volatility based upon historical price changes of the Company’s stock over a period equal to that of the expected life of the option. In March 1996, the Board of Directors adopted and, in February 1997, the shareholders approved the 1996 Employee Incentive Stock Option Plan covering an aggregate of 450,000 1,125,000 1,000 7.60 15,000 7.60 422,650 151,945 913,500 130,000 In October 1998, the Board of Directors adopted and, in January 1999, the shareholders approved the 1998 Employee Stock Option Plan (the "1998 Plan") covering an aggregate of 500,000 6,000 7.60 81,598 477,677 65,275 In October 2000, the Board of Directors adopted and, in February 2001, the shareholders approved the 2001 Employee Stock Option Plan (the "2001 Plan") covering an aggregate of 1,000,000 9,968 1.82 5.82 375,318 865,975 251,261 In September 2005, the Board of Directors adopted and, in December 2005, the shareholders approved, the 2005 Employee Equity Incentive Plan (the "2005 Plan") covering an aggregate of 500,000 200,000 223,725 85 6.18 275,650 47,750 47,125 625 120,000 2.41 5.42 67,500 7,500 12,500 In December 2009, the Board of Directors and shareholders adopted the 2009 Employee Equity Incentive Plan (the "2009 Plan") covering an aggregate of 500,000 200,000 345,423 1.82 6.18 133,477 89,025 67,925 21,100 138,750 2.41 6.71 26,250 30,000 35,000 In December 2012, the Board of Directors and shareholders adopted the 2012 Employee Equity Incentive Plan (the “2012 Plan”) covering an aggregate of 500,000 200,000 442,750 4.68 13.89 8,750 7,000 48,500 75,000 13.20 15,000 125,000 In November 2014, the Board of Directors adopted and, in February 2015, the shareholders approved the 2014 Employee Equity Incentive Plan (the “2014 Plan”) covering an aggregate of 750,000 180,000 11.88 12.77 570,000 The selection of participants, allotments of shares and determination of price and other conditions relating to options are determined by the Board of Directors or a committee thereof, depending on the Plan, and in accordance with Rule 4350(c) of the Corporate Governance Requirements applicable to Nasdaq-listed companies. Incentive stock options granted under the Plans are exercisable for a period of up to ten years from the date of grant at an exercise price which is not less than the fair market value of the Common Stock on the date of the grant, except that the term of an incentive stock option granted under the Plans to a shareholder owning more than 10% of the outstanding Common Stock may not exceed five years and its exercise price may not be less than 110% of the fair market value of the Common Stock on the date of grant. Options shall become exercisable at such time and in such installments as provided in the terms of each individual option agreement. Options Weighted Average Weighted Remaining Number Average Contractual Aggregate of Exercise Life Intrinsic Shares Price Years Value Outstanding as of June 30, 2014 1,663,329 $ 3.88 Granted 549,000 10.11 Exercised (579,463) 4.11 $ 1,592,472 Forfeited (47,250) 7.70 Expired (28,000) 8.00 Outstanding as of June 30, 2015 1,557,616 $ 5.80 6.4 $ 6,553,821 Vested and exercisable at June 30, 2015 620,256 $ 3.19 5.0 $ 3,911,604 Outstanding as of June 30, 2013 1,729,991 $ 3.65 Granted 324,000 4.94 Exercised (178,212) 2.72 $ 341,479 Forfeited (50,250) 4.31 Expired (162,200) 4.67 Outstanding as of June 30, 2014 1,663,329 $ 3.88 5.2 $ 4,879,106 Vested and exercisable at June 30, 2014 967,056 $ 3.81 4.3 $ 2,937,802 Outstanding as of June 30, 2012 1,820,930 $ 3.60 Granted 357,500 3.83 Exercised (150,964) 2.45 $ 86,972 Forfeited (95,775) 2.41 Expired (201,700) 5.10 Outstanding as of June 30, 2013 1,729,991 $ 3.65 5.4 $ 2,937,132 Vested and exercisable at June 30, 2013 1,104,817 $ 3.97 3.6 $ 1,554,007 The following table summarizes information about stock options outstanding at June 30, 2015: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Contractual Average Average Exercise Life Exercise Exercise Prices Number (Yrs.) Price Number Price $0.85-2.96 605,386 5.5 $ 2.39 455,051 $ 2.28 $3.45-4.68 220,850 6.4 $ 4.66 44,975 $ 4.56 $5.42-13.89 731,380 7.4 $ 8.96 120,230 $ 6.14 1,557,616 6.4 $ 5.80 620,256 $ 3.19 As of June 30, 2015, 2014 and 2013, 1,557,616 1,663,329 1,729,991 812,725 564,475 854,725 All outstanding options expire between September 2015 and May 2025 and vest over periods of up to four years. The total number of unvested options as of June 30, 2015 are 937,361 3,583,407

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Employment Agreement On May 22, 2015, the Employment Agreement, dated July 1, 2014, by and between Michael A. McManus, Jr. and the Company was mutually terminated and replaced by a new Employment Agreement whereby Mr. McManus will continue to serve as the Company's President and Chief Executive Officer (the "McManus Agreement"). The McManus Agreement, effective as of May 22, 2015, has an initial term expiring June 30, 2017 and renews for successive one-year periods thereafter unless terminated by either party not less than ninety (90) days prior to the end of the then-current term. The McManus Agreement provides for an annual base salary of (i) $ 299,000 325,000 100,000 11.88 Mr. McManus is entitled under the McManus Agreement to participate in any plans and programs made available to the executive employees of the Company generally. The Company can terminate the McManus Agreement for cause (as defined in the McManus Agreement). Mr. McManus can terminate the McManus Agreement for good reason (as defined in the McManus Agreement). If Mr. McManus terminates the McManus Agreement for good reason, the Company must (i) pay him an amount equal to two times his total compensation (annual base salary plus bonus) at the highest rate paid him at any time during the aggregate time he has been employed by the Company, payable in a lump sum within sixty days of termination of employment, and (ii) pay premiums for medical, dental, vision, hospitalization and long term care coverage under Company plans for a period of twenty-four (24) months. Mr. McManus is entitled to severance pay and benefits if he terminates his employment with the Company following a Change in Control (as defined in the McManus Agreement), to provide him with an incentive to remain with the Company and consummate a strategic corporate sale or transaction that maximizes shareholder value. Severance pay and benefits are triggered upon (i) his Involuntary Termination without Cause (as defined in the McManus Agreement) for a reason other than death or Disability (as defined in the McManus Agreement) or (ii) as a result of a Constructive Termination (as defined in the McManus Agreement) which in either case occurs: (x) during the period not to exceed twenty-four (24) months after the effective date of a Change in Control, or (y) before the effective date of a Change in Control, but after the first date on which the Board of Directors and/or senior management of the Company has entered into formal negotiations with a potential acquirer that results in the consummation of a Change in Control. In the event that pay and benefits are so triggered, Mr. McManus (A) is entitled to receive severance pay in an amount equal to two (2) times the sum of (a) his annual base pay and (b) bonus at the highest rate paid him for any fiscal year during the aggregate period of his employment by the Company, payable in cash in a lump sum; the payment of premiums for medical, dental, vision, hospitalization and long term care coverage under Company plans for a period of twenty-four (24) months; (B) has the right, for a period of (i) ninety (90) days for stock options granted under any of the Company's Employee Stock Option Plans adopted prior to 2005 and (ii) two (2) years for stock options granted under the Company's 2005 Employee Equity Incentive Plan, 2009 Employee Equity Incentive Plan, 2014 Employee Equity Incentive Plan and any Plan adopted after the effective date of the McManus Agreement, following his Termination Date (as defined in the McManus Agreement) to exercise the options to the extent such options are otherwise vested and exercisable as of the Termination Date under the terms of the applicable stock option McManus Agreement(s) and plan(s); and (C) will vest in all unvested stock option grants with respect to options granted after July 1, 2012. Mr. McManus has also agreed in the McManus Agreement to an eighteen month post-termination covenant not-to-compete, as well as other customary covenants concerning non-solicitation and non-disclosure of confidential information of the Company. The Company and Mr. McManus had previously entered into two letter agreements (the "Letter Agreements") providing for the exercise of vested options by Mr. McManus (i) for a ninety (90) day period after his retirement with respect to stock options granted under certain of the Company's stock option plans and (ii) for two (2) years after Mr. McManus terminates his employment with the Company in the event of a Change-in-Control (as defined in the applicable stock option plans) and he is eligible for the severance benefits provided for by the McManus Agreement. The Company and Mr. McManus have entered into a letter agreement which makes clear that the terms and conditions of the Letter Agreements continue to be in full force and effect and apply to the McManus Agreement. Purchase Commitments As of June 30, 2015, 2014 and 2013, the Company had purchase and inventory commitments totaling $ 2,982,198 2,300,949 1,510,566 Contingencies The Company and its subsidiaries are from time to time involved in ordinary and routine litigation. Management presently believes that the ultimate outcome of these proceedings, individually or in the aggregate, will not have a material adverse effect on the Company’s financial position, cash flows or result of operations. Nevertheless, litigation is subject to inherent uncertainties and an unfavorable ruling could occur. An unfavorable ruling could include money damages and, in such event, could result in a material adverse impact on the Company’s results of operations in the year in which the ruling occurs. On July 19, 2011, Misonix entered into a Distribution Agreement (the “Distribution Agreement”) with Puricore, Inc. (“Puricore”). Pursuant to the Distribution Agreement, the Company had been granted the right to distribute PuriCore’s Vashe ® During the fiscal fourth quarter 2013, the Company sent a notice to terminate the Distribution Agreement due to management’s belief that the products subject to the Distribution Agreement were non-conforming. Puricore disputed the Company’s ability to terminate the Distribution Agreement. On October 11, 2013, the Company and Puricore mutually terminated the Distribution Agreement and signed a Settlement Agreement resolving all issues without the payment of any monies by either party. A reversal of the previously accrued and unpaid contractual minimum gross profit requirement in the amount of $ 439,508

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions Stavros G. Vizirgianakis was appointed to Misonix’s Board of Directors on May 7, 2013. During the fiscal year ended June 30, 2014, Mr. Vizirgianakis owned (i) a controlling interest in MD Solutions Australasia PTY Ltd. (“MD Solutions”) and (ii) an interest in Surgical Innovations (“SI”). MD Solutions is an independent distributor for the Company outside of the United States. Applied BioSurgical, a company formerly owned by Mr. Vizirgianakis’ father, was an independent distributor for the Company outside of the United States. SI purchased certain of the Company’s products from Applied BioSurgical during the fiscal year ended June 30, 2014. Mr. Vizirgianakis disposed of his interest in each of MD Solutions and SI during the fiscal year ended June 30, 2014. For the years ended June 30, Applied Bio Surgical 2015 2014 2013 Sales $ 540,185 $ 378,287 $ 489,592 Accounts receivable 294,683 147,585 130,123 MD Solutions 2015 2014 2013 Sales $ - $ 120,118 $ 335,274 Accounts receivable - 1,785 18,700

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	10. Income Taxes Open tax years related to federal and state income tax filings are for the years ended June 30, 2012, 2013, 2014 and 2015. The Company’s net operating loss carryforwards from closed years can be adjusted by the tax authorities when they are utilized in an open year. The Company files state tax returns in California, New York and Texas. The Company's foreign subsidiaries, Misonix Ltd. and Misonix Urology Services Limited (formerly, UKHIFU Limited), filed tax returns in the United Kingdom. Open years related to the United Kingdom for filing are June 30, 2013, 2014 and 2015. As of June 30, 2015 and 2014, the Company has no material unrecognized tax benefits and no accrued interest and penalties. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. June 30, 2015 2014 2013 Deferred tax assets - current Bad debt reserves 44,697 47,227 56,842 Inventory 490,789 612,420 611,272 Accruals and allowances 13,796 13,512 13,504 License fee and other income 7,886 31,428 59,602 Net operating loss carryforwards 1,561,548 - - Other - 24,031 22,512 2,118,716 728,618 763,732 Valuation allowance - (728,618) (763,732) Net deferred tax assets - current 2,118,716 - - Deferred tax assets - non-current Net operating loss carryforwards 628,730 4,636,476 5,235,264 Tax credits 842,739 702,776 534,163 Stock based compensation 161,580 225,925 225,793 Deferred gain - HIFU and Labcaire 163,610 196,773 203,946 Depreciation 167,597 - - Other 12,709 - - 1,976,965 5,761,950 6,199,166 Valuation allowance (628,730) (5,403,529) (5,899,270) 1,348,235 358,421 299,896 Deferred tax (liabilities) - non-current Amortization (574,523) (358,421) (299,896) Net deferred tax assets - non-current 773,712 - - Prior to June 30, 2014 and through March 31, 2015, the Company had a full valuation allowance recorded against deferred tax assets. As of the year ended June 30, 2015, the Company reduced the valuation allowance by $ 5,503,417 1,499,297 2,892,000 As of June 30, 2015, the Company had approximately $ 4,498,000 2031 2033 672,000 170,000 Year ended June 30, 2015 2014 2013 Current: Federal $ 59,686 $ 24,613 $ (79,667) State 44,361 6,017 4,471 Total current 104,047 30,630 (75,196) Deferred: Federal (2,845,039) - - State (43,640) - - Total deferred (2,888,679) - - $ (2,784,632) $ 30,630 $ (75,196) Year ended June 30, 2015 2014 2013 Tax at federal statutory rates $ 856,604 $ 393,451 $ (993,461) State income taxes, net of federal benefit 29,278 3,971 2,951 Research credit (70,401) (140,044) (58,777) Stock-based compensation 303,398 236,941 166,080 Valuation allowance (3,914,045) (486,106) 782,808 Travel and entertainment 21,508 21,587 24,860 Other (10,974) 830 343 $ (2,784,632) $ 30,630 $ (75,196)

Licensing Agreements for Medica

Licensing Agreements for Medical Technology	12 Months Ended
	Jun. 30, 2015
Licensing Agreements For Medical Technology [Abstract]
Licensing Agreements For Medical Technology [Text Block]	11. Licensing Agreements for Medical Technology In October 1996, the Company entered into a License Agreement (the "USS License") with United States Surgical (now, Medtronic plc) for a twenty-year period, expiring October 2016, covering the further development and commercial exploitation of the Company's medical technology relating to laparoscopic products, which uses high frequency sound waves to coagulate and divide tissue for both open and laparoscopic surgery. The USS License gives Covidien exclusive worldwide marketing and sales rights for this technology. Under the USS License, the Company has received $ 475,000 4,162,000 3,619,000 2,369,000

Employee Profit Sharing Plan

Employee Profit Sharing Plan	12 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Compensation and Employee Benefit Plans [Text Block]	12. Employee Profit Sharing Plan The Company sponsors a retirement plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended (the “Code”) for all full time employees. Participants may contribute a percentage of compensation not to exceed the maximum allowed under the Code, which was $ 17,500 23,000 50 years 10 46,636 38,320 38,510

Quarterly Results (unaudited)

Quarterly Results (unaudited)	12 Months Ended
	Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	13. Quarterly Results (unaudited) FISCAL 2015 Q1 Q2 Q3 Q4 YEAR Net sales $ 4,539,337 $ 5,601,008 $ 5,314,797 $ 6,749,436 $ 22,204,578 Cost of goods sold 1,586,105 1,767,175 1,670,359 2,256,637 7,280,276 Gross profit 2,953,232 3,833,833 3,644,438 4,492,799 14,924,302 Operating expenses: Selling expenses 2,019,286 2,085,174 2,465,803 2,492,432 9,062,695 General and administrative expenses 1,246,078 1,534,784 1,583,399 1,619,362 5,983,623 Research and development expenses 437,591 324,301 407,773 423,258 1,592,923 Total operating expenses 3,702,955 3,944,259 4,456,975 4,535,052 16,639,241 Loss from operations (749,723) (110,426) (812,537) (42,253) (1,714,939) Other income/(expense): Interest income 25 19 12 19 75 Royalty income and license fees 1,147,951 1,044,941 1,032,027 1,031,402 4,256,321 Other (5,679) (4,847) (6,452) (5,055) (22,033) Total other income 1,142,297 1,040,113 1,025,587 1,026,366 4,234,363 Income from continuing operations before income taxes 392,574 929,687 213,050 984,113 2,519,424 Income tax expense/(benefit) 14,352 33,465 8,406 (2,840,855) (2,784,632) Net income from continuing operations $ 378,222 $ 896,222 $ 204,644 $ 3,824,968 $ 5,304,056 Discontinued operations: Net income from discontinued operations net of income tax expense/(benefit) of $0,$0, $5,280 and ($4,153), respectively 4,975 4,975 249,696 7,469 267,115 Net income from discontinued operations 4,975 4,975 249,696 7,469 267,115 Net income $ 383,197 $ 901,197 $ 454,340 $ 3,832,437 $ 5,571,171 Net income per share from continuing operations - Basic $ 0.05 $ 0.12 $ 0.03 $ 0.50 $ 0.70 Net income per share from discontinued operations - Basic 0.00 0.00 0.03 0.00 0.04 Net income per share - Basic $ 0.05 $ 0.12 $ 0.06 $ 0.50 $ 0.74 Net income per share from continuing operations - Diluted $ 0.05 $ 0.11 $ 0.02 $ 0.46 $ 0.66 Net income per share from discontinued operations - Diluted 0.00 0.00 0.03 0.00 0.03 Net income per share - Diluted $ 0.05 $ 0.11 $ 0.05 $ 0.46 $ 0.69 FISCAL 2014 Q1 Q2 Q3 Q4 YEAR Net sales $ 3,075,584 $ 4,122,059 $ 4,284,645 $ 5,578,147 $ 17,060,435 Cost of goods sold 1,345,330 1,229,409 A 1,431,766 1,927,362 5,933,867 Gross profit 1,730,254 2,892,650 2,852,879 3,650,785 11,126,568 Operating expenses: Selling expenses 1,828,830 1,683,699 1,913,795 1,846,402 7,272,726 General and administrative expenses 1,221,315 1,120,926 1,176,047 1,172,767 4,691,055 Research and development expenses 472,888 435,019 406,466 397,378 1,711,751 Total operating expenses 3,523,033 3,239,644 3,496,308 3,416,547 13,675,532 (Loss)/income from operations (1,792,779) (346,994) (643,429) 234,238 (2,548,964) Other income/(expense): Interest income 19 19 18 13 69 Royalty income and license fees 912,794 809,392 830,702 1,172,548 3,725,436 Other (6,261) (5,304) (5,121) (2,645) (19,331) Total other income 906,552 804,107 825,599 1,169,916 3,706,174 (Loss)/income from continuing operations before income taxes (886,227) 457,113 182,170 1,404,154 1,157,210 Income tax expense 2,750 2,750 8,376 16,754 30,630 Net (loss)/income from continuing operations $ (888,977) $ 454,363 $ 173,794 $ 1,387,400 $ 1,126,580 Discontinued operations: Net income from discontinued operations net of income tax expense of $0, $0, $0 and $3,182, respectively 4,975 4,975 254,976 1,793 266,719 Net income from discontinued operations 4,975 4,975 254,976 1,793 266,719 Net (loss)/income $ (884,002) $ 459,338 $ 428,770 $ 1,389,193 $ 1,393,299 Net (loss)/income per share from continuing operations - Basic $ (0.12) $ 0.06 $ 0.02 $ 0.19 $ 0.15 Net income per share from discontinued operations - Basic 0.00 0.00 0.04 0.00 0.04 Net (loss)/income per share - Basic $ (0.12) $ 0.06 $ 0.06 $ 0.19 $ 0.19 Net (loss)/income per share from continuing operations - Diluted $ (0.12) $ 0.06 $ 0.02 $ 0.18 $ 0.15 Net income per share from discontinued operations - Diluted 0.00 0.00 0.03 0.00 0.04 Net (loss)/income per share - Diluted $ (0.12) $ 0.06 $ 0.05 $ 0.18 $ 0.19 A. Includes the reversal of $439,508 of previously accrued and unpaid contractual minimum gross profit requirement pursuant to a signed Settlement Agreement. FISCAL 2013 Q1 Q2 Q3 Q4 YEAR Net sales $ 4,570,525 $ 3,474,231 $ 3,023,487 $ 3,758,983 $ 14,827,226 Cost of goods sold 1,843,899 1,626,965 1,482,329 2,474,054 B 7,427,247 Gross profit 2,726,626 1,847,266 1,541,158 1,284,929 7,399,979 Operating expenses: Selling expenses 1,458,564 1,545,585 1,764,718 2,007,337 6,776,204 General and administrative expenses 1,042,332 1,092,726 1,155,613 1,155,818 4,446,489 Research and development expenses 397,131 366,257 379,901 352,769 1,496,058 Total operating expenses 2,898,027 3,004,568 3,300,232 3,515,924 12,718,751 Loss from operations (171,401) (1,157,302) (1,759,074) (2,230,995) (5,318,772) Other income/(expense): Interest income 13 25 18 19 75 Interest expense - - - (7) (7) Royalty income and license fees 222,679 522,385 1,025,153 741,438 2,511,655 Royalty(expense)/recovery (3,698) (1,415) (182) (8,066) (13,361) Other (7,577) (18,608) (25,378) (49,970) (101,533) Total other income 211,417 502,387 999,611 683,414 2,396,829 Income/(loss) from continuing operations before income taxes 40,016 (654,915) (759,463) (1,547,581) (2,921,943) Income tax expense/(benefit) 1,500 2,329 (59,126) (19,899) (75,196) Net income/(loss) from continuing operations $ 38,516 $ (657,244) $ (700,337) $ (1,527,682) $ (2,846,747) Discontinued operations: Net income/(loss) from discontinued operations net of income tax expense/(benefit) of $0, $0, $82,968 and $(3,301), respectively 6,318 3,475 172,007 (6,018) 175,782 Net income/(loss) from discontinued operations 6,318 3,475 172,007 (6,018) 175,782 Net income/(loss) $ 44,834 $ (653,769) $ (528,330) $ (1,533,700) $ (2,670,965) Net income/(loss) per share from continuing operations - Basic $ 0.01 $ (0.09) $ (0.10) $ (0.22) $ (0.40) Net income per share from discontinued operations - Basic - - 0.02 - 0.02 Net income/(loss) per share - Basic $ 0.01 $ (0.09) $ (0.08) $ (0.22) $ (0.38) Net income/(loss) per share from continuing operations - Diluted $ 0.01 $ (0.09) $ (0.10) $ (0.22) $ (0.40) Net income per share from discontinued operations - Diluted - - 0.02 - 0.02 Net income/(loss) per share - Diluted $ 0.01 $ (0.09) $ (0.08) $ (0.22) $ (0.38) B. Includes additional inventory reserves of $835,000.

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Jun. 30, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II Column C Column B Additions Column E Balance at charged Balance at Column A beginning to cost and Column D end of Description of period expenses (Deductions) period Allowance for doubtful accounts: Year ended June 30: 2015 $ 136,868 $ (10,000) $ - $ 126,868 2014 $ 214,641 $ (39,811) $ (37,962) (A) $ 136,868 2013 $ 155,739 $ 60,000 $ (1,098) (A) $ 214,641 (A) Reduction in allowance for doubtful accounts due to write off of certain accounts receivable balances. Column C Column B Additions Column E Balance at charged Balance at Column A beginning to cost and Column D end of Description of period expenses (Deductions) period Reserve for obsolescence Year ended June 30: 2015 $ 1,337,586 $ 87,041 $ (436,856) (B) $ 987,771 2014 $ 1,349,526 $ 107,289 $ (119,229) (B) $ 1,337,586 2013 $ 443,328 $ 916,198 $ - $ 1,349,526 (B) Reduction in reserve for obsolescence due to the write off of obsolete items.

Basis of Presentation, Organi23

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements of MISONIX, INC. (“Misonix” or the “Company”) include the accounts of Misonix and its 100
Organization and Business Policy [Policy Text Block]	Organization and Business Misonix is a surgical device company, operating in one business segment, that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications. The Company’s revenues are generated from various regions throughout the world. Sales by the Company outside the United States are made through distributors. Sales made in the United States are made primarily through representative agents. For the years ended June 30, 2015 2014 United States $ 10,797,920 $ 8,185,468 Australia 364,156 120,118 Europe 3,385,603 2,387,376 Asia 4,125,662 3,572,056 Canada and Mexico 836,188 779,833 South America 911,711 1,165,124 South Africa 540,185 378,287 Middle East 1,243,153 472,173 $ 22,204,578 $ 17,060,435 For the years ended June 30, 2014 2013 United States $ 8,185,468 $ 7,649,041 Australia 120,118 358,509 Europe 2,387,376 3,062,307 Asia 3,572,056 1,619,255 Canada and Mexico 779,833 516,088 South America 1,165,124 735,060 South Africa 378,287 489,756 Middle East 472,173 397,210 $ 17,060,435 $ 14,827,226
Discontinued Operations, Policy [Policy Text Block]	For the years ended June 30, 2015 2014 2013 Revenues $ 18,242 $ 19,901 $ 19,901 Income from discontinued operations, before tax $ 18,242 $ 19,901 $ 5,449 Gain on sale of discontinued operations 250,000 250,000 250,000 Income tax benefit/(expense) (1,127) (3,182) (79,667) Net income from discontinued operations, net of tax $ 267,115 $ 266,719 $ 175,782 High Intensity Focused Ultrasound Technology In consideration for the May 2010 sale of its rights to the high intensity focused ultrasound technology to SonaCare Medical (“SonaCare”), Misonix will receive up to approximately $ 5.8 7 3 5 5.8 Commencing 90 days after each December 31st and beginning December 31, 2011 the payments due to Misonix will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million 1,004,788
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions. At June 30, 2015, these financial institutions held cash that was approximately $ 9,375,735
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Major Customers and Concentration of Credit Risk Included in sales from continuing operations are sales to Cicel (Beijing) Science and Tech Co. Ltd. (“Cicel”) of $ 2,974,086 2,495,960 619,537 3,820 5,226 110,437 497,581 636,085 1,425,708 4,162,000 3,619,000 2,369,000 1,012,000 892,000 1,000 121,000 586,000 606,000 1,805,000 1,332,000
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 90
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost (first-in, first-out) or market and consist of raw materials, work-in process and finished goods and include purchased materials, direct labor and manufacturing overhead. Management evaluates the need to record adjustments to write down inventory to the lower of cost or market on a quarterly basis. The Company’s policy is to assess the valuation of all inventories, including raw materials, work-in-process and finished goods and it writes down its inventory for estimated obsolescence based upon the age of inventory and assumptions about future demand and usage. During the year ended June 30, 2013 the Company also established inventory reserves aggregating approximately $ 835,000
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property, plant and equipment are recorded at cost. Minor replacements and maintenance and repair expenses are charged to expense as incurred. Depreciation of property and equipment is provided using the straight-line method over estimated useful lives ranging from 3 to 5 years. Leasehold improvements are amortized over the life of the lease or the useful life of the related asset, whichever is shorter. The Company's policy is to periodically evaluate the appropriateness of the lives assigned to property, plant and equipment and make adjustments if necessary. Inventory items included in property, plant and equipment are depreciated using the straight line method over estimated useful lives of 3 to 5 years. See Note 4.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company records revenue upon shipment for products shipped F.O.B. shipping point. Products shipped F.O.B. destination points are recorded as revenue when received at the point of destination. Shipments under agreements with distributors are not subject to return, and payment for these shipments is not contingent on sales by the distributor. Accordingly, the Company recognizes revenue on shipments to distributors in the same manner as with other customers. Fees from exclusive license agreements are recognized ratably over the terms of the respective agreements. Service contracts and royalty income are recognized when earned. The Company presents taxes collected from customers and remitted to governmental authorities in the consolidated statements of operations on a net basis.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The carrying values of intangible and other long-lived assets, excluding goodwill, are periodically reviewed to determine if any impairment indicators are present. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization and depreciation period, their carrying values are reduced to estimated fair value. Impairment indicators include, among other conditions, cash flow deficits, an historic or anticipated decline in revenue or operating profit, adverse legal or regulatory developments, accumulation of costs significantly in excess of amounts originally expected to acquire the asset and a material decrease in the fair value of some or all of the assets. Assets are grouped at the lowest levels for which there are identifiable cash flows that are largely independent of the cash flows generated by other asset groups. No such impairment was deemed to exist in fiscal 2015, 2014 or 2013.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill is not amortized. We review goodwill for impairment annually and whenever events or changes indicate that the carrying value of an asset may not be recoverable. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of significant assets or products. Application of these impairment tests requires significant judgments, including estimation of cash flows, which is dependent on internal forecasts, estimation of the long term rate of growth for the Company’s business, the useful lives over which cash flows will occur and determination of the Company’s weighted average cost of capital. We primarily utilize a discontinued cashflow model in determining the fair value which consists of Level 3 inputs. Changes in the projected cash flows and discount rate estimates and assumptions underlying the valuation of goodwill could materially affect the determination of fair value at acquisition or during subsequent periods when tested for impairment. The Company completed its annual goodwill impairment tests for fiscal 2015 and 2014 as of June 30th each year. No impairment of goodwill was deemed to exist in fiscal 2015, 2014 or 2013.
Goodwill and Intangible Assets, Policy [Policy Text Block]	The cost of acquiring or processing patents is capitalized at cost. This amount is being amortized using the straight-line method over the estimated useful lives of the underlying assets, which is approximately 17 years. Net patents reported in intangible and other assets totaled $ 566,028 611,355 791,551 641,469 150,000 83,000 75,000 Net customer relationships are amortized over 5 years and reported in intangible and other assets and totaled $ 40,000 200,000 760,000 600,000 160,000 Net reacquired contractual rights from Aesculap reported in intangible and other assets totaled $ 178,983 0 149,153 0 149,153 0 0 Customer Reacquired Patents Relationships Contractual Rights 2016 $ 85,636 $ 40,000 $ 178,983 2017 80,540 - - 2018 77,960 - - 2019 70,353 - - 2020 47,425 - - Thereafter 204,114 - - $ 566,028 $ 40,000 $ 178,983
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible. Should management determine that it is more likely than not that some portion of the deferred tax asset will not be realized, a valuation allowance against the deferred tax asset would be established in the period such determination was made. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company classifies income tax related interest and penalties as a component of income tax expense.
Earnings Per Share, Policy [Policy Text Block]	Basic income (loss) per common share ("Basic EPS") is computed by dividing income (loss) by the weighted average number of common shares outstanding using the treasury stock method. Diluted income (loss) per common share ("Diluted EPS") is computed by dividing income (loss) by the weighted average number of common shares and the dilutive common share equivalents and convertible securities then outstanding. For the years ended June 30, 2015 2014 2013 Basic shares 7,580,450 7,232,004 7,050,423 Dilutive effect of stock options 513,669 235,588 - Diluted shares 8,094,119 7,467,592 7,050,423 Excluded from the calculation to Diluted EPS are options to purchase 257,000 312,630 1,729,991
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income/(Loss) Total comprehensive income/(loss) was $ 5,571,171 1,393,299 2,670,965
Research and Development Expense, Policy [Policy Text Block]	Research and Development All research and development expenses are expensed as incurred and are included in operating expenses.
Advertising Costs, Policy [Policy Text Block]	Advertising Expense The cost of advertising is expensed in the period the advertising first takes place. The Company incurred approximately $ 155,000 100,000 141,000
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are used for but not limited to, establishing the allowance for doubtful accounts, valuation of inventory, depreciation, asset impairment evaluations and establishing deferred tax assets and stock-based compensation. Actual results could differ from those estimates.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Shipping and handling fees for the fiscal years ended June 30, 2015, 2014 and 2013 were approximately $ 62,000 75,000 47,000 87,000 85,000 101,000
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company measures compensation cost for all share based payments at fair value and recognizes the cost over the vesting period. The Company utilizes the straight line amortization method to recognize the expense associated with the awards with graded vesting terms.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-08, “Presentation of Financial Statements (Topic 205)” and “Property, Plant and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” The amendments in the ASU change the criteria for reporting discontinued operations while enhancing related disclosures. The amendments in the ASU are effective in the first quarter of 2015. The adoption of ASU 2014-08 did not have a material impact on the Company’s consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. This pronouncement has been officially deferred for one year. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Basis of Presentation, Organi24

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	The following is an analysis of net sales from continuing operations by geographic region: For the years ended June 30, 2015 2014 United States $ 10,797,920 $ 8,185,468 Australia 364,156 120,118 Europe 3,385,603 2,387,376 Asia 4,125,662 3,572,056 Canada and Mexico 836,188 779,833 South America 911,711 1,165,124 South Africa 540,185 378,287 Middle East 1,243,153 472,173 $ 22,204,578 $ 17,060,435 For the years ended June 30, 2014 2013 United States $ 8,185,468 $ 7,649,041 Australia 120,118 358,509 Europe 2,387,376 3,062,307 Asia 3,572,056 1,619,255 Canada and Mexico 779,833 516,088 South America 1,165,124 735,060 South Africa 378,287 489,756 Middle East 472,173 397,210 $ 17,060,435 $ 14,827,226
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	For the years ended June 30, 2015 2014 2013 Revenues $ 18,242 $ 19,901 $ 19,901 Income from discontinued operations, before tax $ 18,242 $ 19,901 $ 5,449 Gain on sale of discontinued operations 250,000 250,000 250,000 Income tax benefit/(expense) (1,127) (3,182) (79,667) Net income from discontinued operations, net of tax $ 267,115 $ 266,719 $ 175,782
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The following is a schedule of estimated future amortization expense as of June 30, 2015: Customer Reacquired Patents Relationships Contractual Rights 2016 $ 85,636 $ 40,000 $ 178,983 2017 80,540 - - 2018 77,960 - - 2019 70,353 - - 2020 47,425 - - Thereafter 204,114 - - $ 566,028 $ 40,000 $ 178,983
Schedule of Weighted Average Number of Shares [Table Text Block]	The number of weighted average common shares used in the calculation of Basic EPS and Diluted EPS were as follows: For the years ended June 30, 2015 2014 2013 Basic shares 7,580,450 7,232,004 7,050,423 Dilutive effect of stock options 513,669 235,588 - Diluted shares 8,094,119 7,467,592 7,050,423

Fair Value of Financial Instr25

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The following is a summary of the carrying amounts and estimated fair values of our financial instruments: June 30, 2015 June 30, 2014 Carrying Fair Carrying Fair Amount Value Amount Value Cash and cash equivalents $ 9,623,749 $ 9,623,749 $ 7,039,938 $ 7,039,938 Trade accounts receivable 4,481,247 4,481,247 3,759,152 3,759,152 Trade accounts payable 1,147,414 1,147,414 1,650,323 1,650,323

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories are summarized as follows: June 30, June 30, 2015 2014 Raw material $ 2,096,443 $ 1,820,046 Work-in-process 660,267 410,827 Finished goods 2,536,699 3,337,568 5,293,409 5,568,441 Less valuation reserve 990,246 1,351,091 $ 4,303,163 $ 4,217,350

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment consist of the following: June 30, June 30, 2015 2014 Machinery and equipment $ 1,998,574 $ 1,887,309 Furniture and fixtures 1,287,070 1,234,104 Automobiles 22,328 22,328 Leasehold improvements 476,501 445,879 Demonstration and consignment inventory 3,944,414 2,770,241 7,728,887 6,359,861 Less: accumulated depreciation and amortization (5,672,287) (4,842,009) $ 2,056,600 $ 1,517,852

Accrued Expenses and Other Cu28

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]	The following summarizes accrued expenses and other current liabilities: June 30, June 30, 2015 2014 Accrued payroll and vacation $ 507,172 $ 460,341 Accrued bonuses 300,000 250,000 Accrued commissions 321,440 340,462 Accrued professional and legal fees 97,880 85,832 Income tax payable 71,302 29,506 Deferred income 40,911 102,453 Other $ 193,389 $ 188,656 $ 1,532,094 $ 1,457,250

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2015
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The following is a schedule of future minimum lease payments, by year and in the aggregate, under operating leases with initial or remaining terms of one year or more at June 30, 2015: Operating Leases 2016 $ 347,038 2017 343,580 2018 331,847 Total minimum lease payments $ 1,022,465

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of options at date of grant was estimated using the Black-Scholes option-pricing model utilizing the following assumptions: 2015 2014 2013 Risk-free interest rates 1.6 % 3.0 % 2.5 % Expected option life in years 6.5 6.5 6.5 Expected stock price volatility 61.13 % 76.09 % 75.15 % Expected dividend yield 0 % 0 % 0 %
Schedule of Share-based Compensation, Activity [Table Text Block]	Options Weighted Average Weighted Remaining Number Average Contractual Aggregate of Exercise Life Intrinsic Shares Price Years Value Outstanding as of June 30, 2014 1,663,329 $ 3.88 Granted 549,000 10.11 Exercised (579,463) 4.11 $ 1,592,472 Forfeited (47,250) 7.70 Expired (28,000) 8.00 Outstanding as of June 30, 2015 1,557,616 $ 5.80 6.4 $ 6,553,821 Vested and exercisable at June 30, 2015 620,256 $ 3.19 5.0 $ 3,911,604 Outstanding as of June 30, 2013 1,729,991 $ 3.65 Granted 324,000 4.94 Exercised (178,212) 2.72 $ 341,479 Forfeited (50,250) 4.31 Expired (162,200) 4.67 Outstanding as of June 30, 2014 1,663,329 $ 3.88 5.2 $ 4,879,106 Vested and exercisable at June 30, 2014 967,056 $ 3.81 4.3 $ 2,937,802 Outstanding as of June 30, 2012 1,820,930 $ 3.60 Granted 357,500 3.83 Exercised (150,964) 2.45 $ 86,972 Forfeited (95,775) 2.41 Expired (201,700) 5.10 Outstanding as of June 30, 2013 1,729,991 $ 3.65 5.4 $ 2,937,132 Vested and exercisable at June 30, 2013 1,104,817 $ 3.97 3.6 $ 1,554,007
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes information about stock options outstanding at June 30, 2015: Options Outstanding Options Exercisable Weighted Average Weighted Weighted Range of Contractual Average Average Exercise Life Exercise Exercise Prices Number (Yrs.) Price Number Price $0.85-2.96 605,386 5.5 $ 2.39 455,051 $ 2.28 $3.45-4.68 220,850 6.4 $ 4.66 44,975 $ 4.56 $5.42-13.89 731,380 7.4 $ 8.96 120,230 $ 6.14 1,557,616 6.4 $ 5.80 620,256 $ 3.19

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Set forth below is a table showing the Company’s net sales and accounts receivable for the indicated time periods below with Applied BioSurgical and MD Solutions: For the years ended June 30, Applied Bio Surgical 2015 2014 2013 Sales $ 540,185 $ 378,287 $ 489,592 Accounts receivable 294,683 147,585 130,123 MD Solutions 2015 2014 2013 Sales $ - $ 120,118 $ 335,274 Accounts receivable - 1,785 18,700

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities are presented below: June 30, 2015 2014 2013 Deferred tax assets - current Bad debt reserves 44,697 47,227 56,842 Inventory 490,789 612,420 611,272 Accruals and allowances 13,796 13,512 13,504 License fee and other income 7,886 31,428 59,602 Net operating loss carryforwards 1,561,548 - - Other - 24,031 22,512 2,118,716 728,618 763,732 Valuation allowance - (728,618) (763,732) Net deferred tax assets - current 2,118,716 - - Deferred tax assets - non-current Net operating loss carryforwards 628,730 4,636,476 5,235,264 Tax credits 842,739 702,776 534,163 Stock based compensation 161,580 225,925 225,793 Deferred gain - HIFU and Labcaire 163,610 196,773 203,946 Depreciation 167,597 - - Other 12,709 - - 1,976,965 5,761,950 6,199,166 Valuation allowance (628,730) (5,403,529) (5,899,270) 1,348,235 358,421 299,896 Deferred tax (liabilities) - non-current Amortization (574,523) (358,421) (299,896) Net deferred tax assets - non-current 773,712 - -
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Significant components of the income tax expense (benefit) attributable to continuing operations are as follows: Year ended June 30, 2015 2014 2013 Current: Federal $ 59,686 $ 24,613 $ (79,667) State 44,361 6,017 4,471 Total current 104,047 30,630 (75,196) Deferred: Federal (2,845,039) - - State (43,640) - - Total deferred (2,888,679) - - $ (2,784,632) $ 30,630 $ (75,196)
Federal Income Tax Note [Table Text Block]	The reconciliation of income tax expense (benefit) computed at the Federal statutory tax rates to income tax expense (benefit) is as follows: Year ended June 30, 2015 2014 2013 Tax at federal statutory rates $ 856,604 $ 393,451 $ (993,461) State income taxes, net of federal benefit 29,278 3,971 2,951 Research credit (70,401) (140,044) (58,777) Stock-based compensation 303,398 236,941 166,080 Valuation allowance (3,914,045) (486,106) 782,808 Travel and entertainment 21,508 21,587 24,860 Other (10,974) 830 343 $ (2,784,632) $ 30,630 $ (75,196)

Quarterly Results (unaudited) (

Quarterly Results (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	FISCAL 2015 Q1 Q2 Q3 Q4 YEAR Net sales $ 4,539,337 $ 5,601,008 $ 5,314,797 $ 6,749,436 $ 22,204,578 Cost of goods sold 1,586,105 1,767,175 1,670,359 2,256,637 7,280,276 Gross profit 2,953,232 3,833,833 3,644,438 4,492,799 14,924,302 Operating expenses: Selling expenses 2,019,286 2,085,174 2,465,803 2,492,432 9,062,695 General and administrative expenses 1,246,078 1,534,784 1,583,399 1,619,362 5,983,623 Research and development expenses 437,591 324,301 407,773 423,258 1,592,923 Total operating expenses 3,702,955 3,944,259 4,456,975 4,535,052 16,639,241 Loss from operations (749,723) (110,426) (812,537) (42,253) (1,714,939) Other income/(expense): Interest income 25 19 12 19 75 Royalty income and license fees 1,147,951 1,044,941 1,032,027 1,031,402 4,256,321 Other (5,679) (4,847) (6,452) (5,055) (22,033) Total other income 1,142,297 1,040,113 1,025,587 1,026,366 4,234,363 Income from continuing operations before income taxes 392,574 929,687 213,050 984,113 2,519,424 Income tax expense/(benefit) 14,352 33,465 8,406 (2,840,855) (2,784,632) Net income from continuing operations $ 378,222 $ 896,222 $ 204,644 $ 3,824,968 $ 5,304,056 Discontinued operations: Net income from discontinued operations net of income tax expense/(benefit) of $0,$0, $5,280 and ($4,153), respectively 4,975 4,975 249,696 7,469 267,115 Net income from discontinued operations 4,975 4,975 249,696 7,469 267,115 Net income $ 383,197 $ 901,197 $ 454,340 $ 3,832,437 $ 5,571,171 Net income per share from continuing operations - Basic $ 0.05 $ 0.12 $ 0.03 $ 0.50 $ 0.70 Net income per share from discontinued operations - Basic 0.00 0.00 0.03 0.00 0.04 Net income per share - Basic $ 0.05 $ 0.12 $ 0.06 $ 0.50 $ 0.74 Net income per share from continuing operations - Diluted $ 0.05 $ 0.11 $ 0.02 $ 0.46 $ 0.66 Net income per share from discontinued operations - Diluted 0.00 0.00 0.03 0.00 0.03 Net income per share - Diluted $ 0.05 $ 0.11 $ 0.05 $ 0.46 $ 0.69 FISCAL 2014 Q1 Q2 Q3 Q4 YEAR Net sales $ 3,075,584 $ 4,122,059 $ 4,284,645 $ 5,578,147 $ 17,060,435 Cost of goods sold 1,345,330 1,229,409 A 1,431,766 1,927,362 5,933,867 Gross profit 1,730,254 2,892,650 2,852,879 3,650,785 11,126,568 Operating expenses: Selling expenses 1,828,830 1,683,699 1,913,795 1,846,402 7,272,726 General and administrative expenses 1,221,315 1,120,926 1,176,047 1,172,767 4,691,055 Research and development expenses 472,888 435,019 406,466 397,378 1,711,751 Total operating expenses 3,523,033 3,239,644 3,496,308 3,416,547 13,675,532 (Loss)/income from operations (1,792,779) (346,994) (643,429) 234,238 (2,548,964) Other income/(expense): Interest income 19 19 18 13 69 Royalty income and license fees 912,794 809,392 830,702 1,172,548 3,725,436 Other (6,261) (5,304) (5,121) (2,645) (19,331) Total other income 906,552 804,107 825,599 1,169,916 3,706,174 (Loss)/income from continuing operations before income taxes (886,227) 457,113 182,170 1,404,154 1,157,210 Income tax expense 2,750 2,750 8,376 16,754 30,630 Net (loss)/income from continuing operations $ (888,977) $ 454,363 $ 173,794 $ 1,387,400 $ 1,126,580 Discontinued operations: Net income from discontinued operations net of income tax expense of $0, $0, $0 and $3,182, respectively 4,975 4,975 254,976 1,793 266,719 Net income from discontinued operations 4,975 4,975 254,976 1,793 266,719 Net (loss)/income $ (884,002) $ 459,338 $ 428,770 $ 1,389,193 $ 1,393,299 Net (loss)/income per share from continuing operations - Basic $ (0.12) $ 0.06 $ 0.02 $ 0.19 $ 0.15 Net income per share from discontinued operations - Basic 0.00 0.00 0.04 0.00 0.04 Net (loss)/income per share - Basic $ (0.12) $ 0.06 $ 0.06 $ 0.19 $ 0.19 Net (loss)/income per share from continuing operations - Diluted $ (0.12) $ 0.06 $ 0.02 $ 0.18 $ 0.15 Net income per share from discontinued operations - Diluted 0.00 0.00 0.03 0.00 0.04 Net (loss)/income per share - Diluted $ (0.12) $ 0.06 $ 0.05 $ 0.18 $ 0.19 A. Includes the reversal of $439,508 of previously accrued and unpaid contractual minimum gross profit requirement pursuant to a signed Settlement Agreement. FISCAL 2013 Q1 Q2 Q3 Q4 YEAR Net sales $ 4,570,525 $ 3,474,231 $ 3,023,487 $ 3,758,983 $ 14,827,226 Cost of goods sold 1,843,899 1,626,965 1,482,329 2,474,054 B 7,427,247 Gross profit 2,726,626 1,847,266 1,541,158 1,284,929 7,399,979 Operating expenses: Selling expenses 1,458,564 1,545,585 1,764,718 2,007,337 6,776,204 General and administrative expenses 1,042,332 1,092,726 1,155,613 1,155,818 4,446,489 Research and development expenses 397,131 366,257 379,901 352,769 1,496,058 Total operating expenses 2,898,027 3,004,568 3,300,232 3,515,924 12,718,751 Loss from operations (171,401) (1,157,302) (1,759,074) (2,230,995) (5,318,772) Other income/(expense): Interest income 13 25 18 19 75 Interest expense - - - (7) (7) Royalty income and license fees 222,679 522,385 1,025,153 741,438 2,511,655 Royalty(expense)/recovery (3,698) (1,415) (182) (8,066) (13,361) Other (7,577) (18,608) (25,378) (49,970) (101,533) Total other income 211,417 502,387 999,611 683,414 2,396,829 Income/(loss) from continuing operations before income taxes 40,016 (654,915) (759,463) (1,547,581) (2,921,943) Income tax expense/(benefit) 1,500 2,329 (59,126) (19,899) (75,196) Net income/(loss) from continuing operations $ 38,516 $ (657,244) $ (700,337) $ (1,527,682) $ (2,846,747) Discontinued operations: Net income/(loss) from discontinued operations net of income tax expense/(benefit) of $0, $0, $82,968 and $(3,301), respectively 6,318 3,475 172,007 (6,018) 175,782 Net income/(loss) from discontinued operations 6,318 3,475 172,007 (6,018) 175,782 Net income/(loss) $ 44,834 $ (653,769) $ (528,330) $ (1,533,700) $ (2,670,965) Net income/(loss) per share from continuing operations - Basic $ 0.01 $ (0.09) $ (0.10) $ (0.22) $ (0.40) Net income per share from discontinued operations - Basic - - 0.02 - 0.02 Net income/(loss) per share - Basic $ 0.01 $ (0.09) $ (0.08) $ (0.22) $ (0.38) Net income/(loss) per share from continuing operations - Diluted $ 0.01 $ (0.09) $ (0.10) $ (0.22) $ (0.40) Net income per share from discontinued operations - Diluted - - 0.02 - 0.02 Net income/(loss) per share - Diluted $ 0.01 $ (0.09) $ (0.08) $ (0.22) $ (0.38) B. Includes additional inventory reserves of $835,000.

Basis of Presentation, Organi34

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Revenue from External Customer [Line Items]
Net sales	$ 6,749,436	$ 5,314,797	$ 5,601,008	$ 4,539,337	$ 5,578,147	$ 4,284,645	$ 4,122,059	$ 3,075,584	$ 3,758,983	$ 3,023,487	$ 3,474,231	$ 4,570,525	$ 22,204,578	$ 17,060,435	$ 14,827,226
UNITED STATES
Revenue from External Customer [Line Items]
Net sales													10,797,920	8,185,468	7,649,041
AUSTRALIA
Revenue from External Customer [Line Items]
Net sales													364,156	120,118	358,509
SOUTH AFRICA
Revenue from External Customer [Line Items]
Net sales													540,185	378,287	489,756
EUROPE
Revenue from External Customer [Line Items]
Net sales													3,385,603	2,387,376	3,062,307
ASIA
Revenue from External Customer [Line Items]
Net sales													4,125,662	3,572,056	1,619,255
CANADA AND MEXICO
Revenue from External Customer [Line Items]
Net sales													836,188	779,833	516,088
SOUTH AMERICA
Revenue from External Customer [Line Items]
Net sales													911,711	1,165,124	735,060
MIDDLE EAST
Revenue from External Customer [Line Items]
Net sales													$ 1,243,153	$ 472,173	$ 397,210

Basis of Presentation, Organi35

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues													$ 18,242	$ 19,901	$ 19,901
Income from discontinued operations, before tax													18,242	19,901	5,449
Gain on sale of discontinued operations													250,000	250,000	250,000
Income tax benefit/(expense)	$ 4,153	$ (5,280)	$ 0	$ 0	$ (3,182)	$ 0	$ 0	$ 0	$ 3,301	$ (82,968)	$ 0	$ 0	(1,127)	(3,182)	(79,667)
Net income from discontinued operations, net of tax	$ 7,469	$ 249,696	$ 4,975	$ 4,975	$ 1,793	$ 254,976	$ 4,975	$ 4,975	$ (6,018)	$ 172,007	$ 3,475	$ 6,318	$ 267,115	$ 266,719	$ 175,782

Basis of Presentation, Organi36

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 2) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2,016	$ 85,636
2,017	80,540
2,018	77,960
2,019	70,353
2,020	47,425
Thereafter	204,114
Finite-Lived Intangible Assets, Future Amortization Expense	566,028	$ 611,355
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
2,016	40,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Finite-Lived Intangible Assets, Future Amortization Expense	40,000	$ 200,000
Reacquired Contractual Rights [Member]
Finite-Lived Intangible Assets [Line Items]
2,016	178,983
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Finite-Lived Intangible Assets, Future Amortization Expense	$ 178,983

Basis of Presentation, Organi37

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details 3) - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Weighted Average Number of Shares [Line Items]
Basic shares	7,580,450	7,232,004	7,050,423
Dilutive effect of stock options	513,669	235,588	0
Diluted shares	8,094,119	7,467,592	7,050,423

Basis of Presentation, Organi38

Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended												12 Months Ended
	May. 31, 2010	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Cash, Uninsured Amount		$ 9,375,735												$ 9,375,735
Sales Revenue, Goods, Net, Total		6,749,436	$ 5,314,797	$ 5,601,008	$ 4,539,337	$ 5,578,147	$ 4,284,645	$ 4,122,059	$ 3,075,584	$ 3,758,983	$ 3,023,487	$ 3,474,231	$ 4,570,525	22,204,578	$ 17,060,435	$ 14,827,226
Royalty Expense										8,066	$ 182	$ 1,415	$ 3,698	0	0	13,361
Accounts Receivable, Net, Current, Total		4,481,247				3,759,152								4,481,247	3,759,152
Additional Inventory Reserves		835,000				835,000				$ 835,000				$ 835,000	$ 835,000	$ 835,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount														257,000	312,630	1,729,991
Comprehensive Income (Loss), Net of Tax, Attributable to Parent														$ 5,571,171	$ 1,393,299	$ 2,670,965
Advertising Expense														155,000	100,000	141,000
UNITED STATES
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Accounts Receivable, Net, Current, Total		$ 1,805,000				1,332,000								$ 1,805,000	1,332,000
Minimum [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Accounts Receivable Due Number Of Days														30 days
Property, Plant and Equipment, Estimated Useful Lives														3 years
Maximum [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Accounts Receivable Due Number Of Days														90 days
Property, Plant and Equipment, Estimated Useful Lives														5 years
High Intensity Focused Ultrasound Technology [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Proceeds from Sales of Intangible Assets	$ 5,800,000
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to First Benchmark	7.00%
Proceeds from Sale of Intangible Assets First Benchmark	$ 3,000,000
Sale of Intangible Assets Percentage of Gross Revenue Received as Earn Out Up to Second Benchmark	5.00%
Proceeds from Sale of Intangible Assets Second Benchmark	$ 5,800,000
Payment Sale Of Intangible Assets Description	Commencing 90 days after each December 31st and beginning December 31, 2011 the payments due to Misonix will be the greater of (a) $250,000 or (b) 7% of gross revenues received up to the time the Company has received the first $3 million and thereafter 5% of gross revenues up to the $5.8 million
Payment Sale Of Intangible Assets														$ 1,004,788
Fibra Sonics Ny Inc [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		100.00%												100.00%
Cicel Science [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Accounts Receivable, Net, Current, Total		$ 586,000				606,000								$ 586,000	606,000
Covidien [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Royalty Expense														4,162,000	3,619,000	2,369,000
Accounts Receivable, Net, Current, Total		1,012,000				892,000								1,012,000	892,000
Covidien [Member] | Medical Devices Segment [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Sales Revenue, Goods, Net, Total														3,820	5,226	110,437
Aesculap, Inc [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Accounts Receivable, Net, Current, Total		1,000				121,000								1,000	121,000
Aesculap, Inc [Member] | Medical Devices Segment [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Sales Revenue, Goods, Net, Total														497,581	636,085	1,425,708
Cicel (Beijing) Science and Tech Co. Ltd [Member] | Medical Devices Segment [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Sales Revenue, Goods, Net, Total														2,974,086	2,495,960	619,537
Sales [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Shipping, Handling and Transportation Costs														62,000	75,000	47,000
Selling Expense [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Shipping, Handling and Transportation Costs														87,000	85,000	101,000
Patents [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		566,028				611,355								566,028	611,355
Amortization of Intangible Assets														150,000	83,000	75,000
Finite-Lived Intangible Assets, Accumulated Amortization		791,551				641,469								$ 791,551	641,469
Finite-Lived Intangible Assets, Remaining Amortization Period														17 years
Customer Relationships [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		40,000				200,000								$ 40,000	200,000
Amortization of Intangible Assets														160,000	160,000	160,000
Finite-Lived Intangible Assets, Accumulated Amortization		760,000				600,000								$ 760,000	600,000
Finite-Lived Intangible Assets, Remaining Amortization Period														5 years
Reacquired Contractual Rights [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		178,983												$ 178,983
Reacquired Contractual Rights [Member] | Aesculap, Inc [Member]
Basis of Presentation, Organization and Business and Summary of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Net		178,983				0								178,983	0
Amortization of Intangible Assets														149,153	0	$ 0
Finite-Lived Intangible Assets, Accumulated Amortization		$ 149,153				$ 0								$ 149,153	$ 0

Fair Value of Financial Instr39

Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents, Carrying Amount	$ 9,623,749	$ 7,039,938	$ 5,806,437	$ 6,273,015
Trade accounts receivable, Carrying Amount	4,481,247	3,759,152
Trade accounts payable, Carrying Amount	1,147,414	1,650,323
Cash and cash equivalents, Fair Value	9,623,749	7,039,938
Trade accounts receivable, Fair Value	4,481,247	3,759,152
Trade accounts payable, Fair Value	$ 1,147,414	$ 1,650,323

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Inventory [Line Items]
Raw material	$ 2,096,443	$ 1,820,046
Work-in-process	660,267	410,827
Finished goods	2,536,699	3,337,568
Inventory, Gross	5,293,409	5,568,441
Less valuation reserve	990,246	1,351,091
Inventory, Net, Total	$ 4,303,163	$ 4,217,350

Property, Plant and Equipment41

Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Machinery and equipment	$ 1,998,574	$ 1,887,309
Furniture and fixtures	1,287,070	1,234,104
Automobiles	22,328	22,328
Leasehold improvements	476,501	445,879
Demonstration and consignment inventory	3,944,414	2,770,241
Property, Plant and Equipment, Gross	7,728,887	6,359,861
Less: accumulated depreciation and amortization	(5,672,287)	(4,842,009)
Property, Plant and Equipment, Net	$ 2,056,600	$ 1,517,852

Property, Plant and Equipment42

Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization	$ 981,000	$ 732,000	$ 550,000

Accrued Expenses and Other Cu43

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Accrued payroll and vacation	$ 507,172	$ 460,341
Accrued bonuses	300,000	250,000
Accrued commissions	321,440	340,462
Accrued professional and legal fees	97,880	85,832
Income tax payable	71,302	29,506
Deferred income	40,911	102,453
Other	193,389	188,656
Accrued Expenses and Other Current Liabilities	$ 1,532,094	$ 1,457,250

Leases (Details)

Leases (Details)	Jun. 30, 2015USD ($)
Operating Leased Assets [Line Items]
2,016	$ 347,038
2,017	343,580
2,018	331,847
Total minimum lease payments	$ 1,022,465

Leases (Details Textual)

Leases (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Operating Leased Assets [Line Items]
Sale Leaseback Transaction, Monthly Rental Payments	$ 26,000
Operating Leases, Rent Expense, Net	$ 375,000	$ 392,000	$ 387,000
Lease Expiration Year	2,018

Stock-Based Compensation Plan46

Stock-Based Compensation Plans (Details)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.60%	3.00%	2.50%
Expected option life in years	6 years 6 months	6 years 6 months	6 years 6 months
Expected stock price volatility	61.13%	76.09%	75.15%
Expected dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation Plan47

Stock-Based Compensation Plans (Details 1) - Equity Component [Domain] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding at beginning of period	1,663,329	1,729,991
Number of Shares, Outstanding at end of period	1,557,616	1,663,329	1,729,991
Weighte Average Remaining Contractual Life, Outstanding (in years)	6 years 4 months 24 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding at beginning of period	1,663,329	1,729,991	1,820,930
Number of Shares, Granted	549,000	324,000	357,500
Number of Shares, Exercised	(579,463)	(178,212)	(150,964)
Number of Shares, Forfeited	(47,250)	(50,250)	(95,775)
Number of Shares, Expired	(28,000)	(162,200)	(201,700)
Number of Shares, Outstanding at end of period	1,557,616	1,663,329	1,729,991
Number of Shares, Exercisable and vested	620,256	967,056	1,104,817
Weighted Average Exercise Price, Outstanding at beginning of period	$ 3.88	$ 3.65	$ 3.60
Weighted Average Exercise Price, Granted	10.11	4.94	3.83
Weighted Average Exercise Price, Exercised	4.11	2.72	2.45
Weighted Average Exercise Price, Forfeited	7.70	4.31	2.41
Weighted Average Exercise Price, Expired	8	4.67	5.10
Weighted Average Exercise Price, Outstanding at end of period	5.80	3.88	3.65
Weighted Average Exercise Price, Exercisable and vested	$ 3.19	$ 3.81	$ 3.97
Weighte Average Remaining Contractual Life, Outstanding (in years)	6 years 4 months 24 days	5 years 2 months 12 days	5 years 4 months 24 days
Weighte Average Remaining Contractual Life, Exercisable and vested (in years)	5 years	4 years 3 months 18 days	3 years 7 months 6 days
Aggregate Intrinsic Value, Exercised (in dollars)	$ 1,592,472	$ 341,479	$ 86,972
Aggregate Intrinsic Value, Outstanding (in dollars)	6,553,821	4,879,106	2,937,132
Aggregate Intrinsic Value, Exercisable and vested (in dollars)	$ 3,911,604	$ 2,937,802	$ 1,554,007

Stock-Based Compensation Plan48

Stock-Based Compensation Plans (Details 2) - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number (in shares)	1,557,616	1,663,329	1,729,991
Options Outstanding, Weighted Average Contractual Life (in years)	6 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.80
Options Exercisable, Number (in shares)	620,256
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.19
Range Of Exercise Price 0.85 - 2.96 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number (in shares)	605,386
Options Outstanding, Weighted Average Contractual Life (in years)	5 years 6 months
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.39
Options Exercisable, Number (in shares)	455,051
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.28
Range Of Exercise Price 3.45 - 4.68 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number (in shares)	220,850
Options Outstanding, Weighted Average Contractual Life (in years)	6 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.66
Options Exercisable, Number (in shares)	44,975
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.56
Range Of Exercise Price 5.42 - 13.89 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number (in shares)	731,380
Options Outstanding, Weighted Average Contractual Life (in years)	7 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 8.96
Options Exercisable, Number (in shares)	120,230
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.14

Stock-Based Compensation Plan49

Stock-Based Compensation Plans (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	not to exceed 10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period	549,000	324,000	357,000
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options	$ 3,583,000
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1	2 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 5.70	$ 3.95	$ 3.04
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,557,616	1,663,329	1,729,991
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	812,725	564,475	854,725
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 5.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Description	The selection of participants, allotments of shares and determination of price and other conditions relating to options are determined by the Board of Directors or a committee thereof, depending on the Plan, and in accordance with Rule 4350(c) of the Corporate Governance Requirements applicable to Nasdaq-listed companies. Incentive stock options granted under the Plans are exercisable for a period of up to ten years from the date of grant at an exercise price which is not less than the fair market value of the Common Stock on the date of the grant, except that the term of an incentive stock option granted under the Plans to a shareholder owning more than 10% of the outstanding Common Stock may not exceed five years and its exercise price may not be less than 110% of the fair market value of the Common Stock on the date of grant. Options shall become exercisable at such time and in such installments as provided in the terms of each individual option agreement.
Share-based Compensation Arrangement by Share-based Payment Award, Description	All outstanding options expire between September 2015 and May 2025 and vest over periods of up to four years.
Share-based Compensation Arrangement By Share-based Payment Award Outstanding Options Nonvested in Period Fair Value	$ 3,583,407
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	937,361
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Exercise Price Range 1.82 to 8 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Plan 1996 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	178,295
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	450,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	422,650
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	151,945
Plan 1996 [Member] | Exercise Price Range 5.18 to 7.60 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	1,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 7.60
Plan 1998 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	81,598
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	477,677
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	65,275
Plan 1998 [Member] | Exercise Price Range 7.60 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	6,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 7.60
Plan 2001 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	375,318
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	9,968
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 5.82
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	865,975
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	251,261
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 1.82
Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	275,650
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	47,750
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	47,125
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	625
Plan 2005 [Member] | Exercise Price Range 0.85 to 6.18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	223,725
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 6.18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 85
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	133,477
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	500,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	89,025
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	67,925
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	21,100
Plan 2009 [Member] | Exercise Price Range 1.82 to 6.18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	345,423
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 6.18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 1.82
Plan 2009 [Member] | Exercise Price Range 2.41 to 6.71 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	138,750
Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	8,750
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	442,750
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 13.89
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	7,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	7,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 4.68
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	48,500
Plan 2012 [Member] | Exercise Price Range 13.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 13.20
Directors Plan 1996 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	913,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,125,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	130,000
Directors Plan 1996 [Member] | Exercise Price Range 5.87 to 7.60 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	15,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 7.60
Directors Plan 2005 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	67,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	7,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	12,500
Directors Plan 2005 [Member] | Exercise Price Range 2.41 to 5.42 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	120,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 5.42
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 2.41
Directors Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	26,250
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	30,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	35,000
Directors Plan 2009 [Member] | Exercise Price Range 2.41 to 6.71 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 6.71
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 2.41
Directors Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	200,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	15,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	125,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	$ 723,560
Treasury Stock, Shares, Acquired	47,422
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period	579,463
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares	47,250
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period	28,000
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	570,000
Plan 2014 [Member] | Exercise Price Range 11.88 to 12.77 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	180,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 12.77
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 11.88

Commitment and Contingencies (D

Commitment and Contingencies (Details Textual) - Range [Domain] - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Commitments and Contingencies [Line Items]
Salaries, Wages and Officers' Compensation													$ 325,000
Inventory, Net, Total	$ 4,303,163				$ 4,217,350								4,303,163	$ 4,217,350
Gross Profit, Total	4,492,799	$ 3,644,438	$ 3,833,833	$ 2,953,232	3,650,785	$ 2,852,879	$ 2,892,650	$ 1,730,254	$ 1,284,929	$ 1,541,158	$ 1,847,266	$ 2,726,626	$ 14,924,302	11,126,568	$ 7,399,979
Options Granted To Purchase Shares Of Common Stock													100,000
Exercise Price Of One Time Options													$ 11.88
Fourth Quarter 2013 [Member]
Commitments and Contingencies [Line Items]
Gross Profit, Total													$ 439,508
Purchase Commitments [Member]
Commitments and Contingencies [Line Items]
Inventory, Net, Total	$ 2,982,198				$ 2,300,949				$ 1,510,566				2,982,198	$ 2,300,949	$ 1,510,566
Michael A McManus [Member]
Commitments and Contingencies [Line Items]
Salaries, Wages and Officers' Compensation													$ 299,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Applied BioSurgical [Member]
Related Party Transaction [Line Items]
Sales	$ 540,185	$ 378,287	$ 489,592
Accounts receivable	294,683	147,585	130,123
MD Solutions Australasia PTY Ltd [Member]
Related Party Transaction [Line Items]
Sales	0	120,118	335,274
Accounts receivable	$ 0	$ 1,785	$ 18,700

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Deferred tax assets - current
Bad debt reserves	$ 44,697	$ 47,227	$ 56,842
Inventory	490,789	612,420	611,272
Accruals and allowances	13,796	13,512	13,504
License fee and other income	7,886	31,428	59,602
Net operating loss carryforwards	1,561,548	0	0
Other	0	24,031	22,512
Total deferred tax assets	2,118,716	728,618	763,732
Valuation allowance	0	(728,618)	(763,732)
Net deferred tax assets - current	2,118,716	0	0
Deferred tax assets - non-current
Net operating loss carryforwards	628,730	4,636,476	5,235,264
Tax credits	842,739	702,776	534,163
Stock based compensation	161,580	225,925	225,793
Deferred gain - HIFU and Labcaire	163,610	196,773	203,946
Depreciation	167,597	0	0
Other	12,709	0	0
Deferred Tax Assets, Gross, Noncurrent	1,976,965	5,761,950	6,199,166
Valuation allowance	(628,730)	(5,403,529)	(5,899,270)
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent, Total	1,348,235	358,421	299,896
Deferred tax (liabilities) - non-current
Amortization	(574,523)	(358,421)	(299,896)
Net deferred tax assets - non-current	$ 773,712	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Current:
Federal													$ 59,686	$ 24,613	$ (79,667)
Total current													104,047	30,630	(75,196)
State													44,361	6,017	4,471
Federal													(2,845,039)	0	0
State													(43,640)	0	0
Total deferred	$ 2,892,000												(2,892,428)	0	0
Income tax expense (benefit),Total	$ (2,840,855)	$ 8,406	$ 33,465	$ 14,352	$ 16,754	$ 8,376	$ 2,750	$ 2,750	$ (19,899)	$ (59,126)	$ 2,329	$ 1,500	$ (2,784,632)	$ 30,630	$ (75,196)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Tax at federal statutory rates													$ 856,604	$ 393,451	$ (993,461)
State income taxes, net of federal benefit													29,278	3,971	2,951
Research credit													(70,401)	(140,044)	(58,777)
Stock-based compensation													303,398	236,941	166,080
Valuation allowance													(3,914,045)	(486,106)	782,808
Travel and entertainment													21,508	21,587	24,860
Other													(10,974)	830	343
Income tax expense (benefit),Total	$ (2,840,855)	$ 8,406	$ 33,465	$ 14,352	$ 16,754	$ 8,376	$ 2,750	$ 2,750	$ (19,899)	$ (59,126)	$ 2,329	$ 1,500	$ (2,784,632)	$ 30,630	$ (75,196)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 672,000	$ 672,000
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	170,000	170,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		5,503,417
Deferred Income Tax Expense (Benefit)	2,892,000	(2,892,428)	$ 0	$ 0
Valuation Allowance Deferred Tax Asset Write-off [Member]
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 1,499,297
Minimum [Member]
Income Taxes [Line Items]
Expiration Date Of Tax Credit Carryforward		2,031
Maximum [Member]
Income Taxes [Line Items]
Expiration Date Of Tax Credit Carryforward		2,033
U S Federal [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 4,498,000	$ 4,498,000

Licensing Agreements for Medi56

Licensing Agreements for Medical Technology (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Proceeds from License Fees Received	$ 475,000
Proceeds from Royalties Received	$ 4,162,000	$ 3,619,000	$ 2,369,000

Employee Profit Sharing Plan (D

Employee Profit Sharing Plan (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Employee Profit Sharing Plan [Line Items]
Employee Benefits And Share Based Compensation Age Limit For Discretion	50 years
Supplemental Employee Retirement Plan [Member]
Employee Profit Sharing Plan [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	10.00%
Defined Contribution Plan Employers Matching Contribution Amount	$ 46,636	$ 38,320	$ 38,510
Minimum [Member]
Employee Profit Sharing Plan [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	17,500
Maximum [Member]
Employee Profit Sharing Plan [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 23,000

Quarterly Results (unaudited)58

Quarterly Results (unaudited) (Details) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Net sales	$ 6,749,436	$ 5,314,797	$ 5,601,008	$ 4,539,337	$ 5,578,147	$ 4,284,645	$ 4,122,059	$ 3,075,584	$ 3,758,983	$ 3,023,487	$ 3,474,231	$ 4,570,525	$ 22,204,578	$ 17,060,435	$ 14,827,226
Cost of goods sold	2,256,637	1,670,359	1,767,175	1,586,105	1,927,362	1,431,766	1,229,409	1,345,330	2,474,054	1,482,329	1,626,965	1,843,899	7,280,276	5,933,867	7,427,247
Gross profit	4,492,799	3,644,438	3,833,833	2,953,232	3,650,785	2,852,879	2,892,650	1,730,254	1,284,929	1,541,158	1,847,266	2,726,626	14,924,302	11,126,568	7,399,979
Operating expenses:
Selling expenses	2,492,432	2,465,803	2,085,174	2,019,286	1,846,402	1,913,795	1,683,699	1,828,830	2,007,337	1,764,718	1,545,585	1,458,564	9,062,695	7,272,726	6,776,204
General and administrative expenses	1,619,362	1,583,399	1,534,784	1,246,078	1,172,767	1,176,047	1,120,926	1,221,315	1,155,818	1,155,613	1,092,726	1,042,332	5,983,623	4,691,055	4,446,489
Research and development expenses	423,258	407,773	324,301	437,591	397,378	406,466	435,019	472,888	352,769	379,901	366,257	397,131	1,592,923	1,711,751	1,496,058
Total operating expenses	4,535,052	4,456,975	3,944,259	3,702,955	3,416,547	3,496,308	3,239,644	3,523,033	3,515,924	3,300,232	3,004,568	2,898,027	16,639,241	13,675,532	12,718,751
Loss from operations	(42,253)	(812,537)	(110,426)	(749,723)	234,238	(643,429)	(346,994)	(1,792,779)	(2,230,995)	(1,759,074)	(1,157,302)	(171,401)	(1,714,939)	(2,548,964)	(5,318,772)
Other income/(expense):
Interest income	19	12	19	25	13	18	19	19	19	18	25	13	75	69	75
Interest expense									(7)	0	0	0			(7)
Royalty income and license fees	1,031,402	1,032,027	1,044,941	1,147,951	1,172,548	830,702	809,392	912,794	741,438	1,025,153	522,385	222,679	4,256,321	3,725,436	2,511,655
Royalty expense									(8,066)	(182)	(1,415)	(3,698)	0	0	(13,361)
Other	(5,055)	(6,452)	(4,847)	(5,679)	(2,645)	(5,121)	(5,304)	(6,261)	(49,970)	(25,378)	(18,608)	(7,577)	(22,033)	(19,331)	(101,533)
Total other income	1,026,366	1,025,587	1,040,113	1,142,297	1,169,916	825,599	804,107	906,552	683,414	999,611	502,387	211,417	4,234,363	3,706,174	2,396,829
Income from continuing operations before income taxes	984,113	213,050	929,687	392,574	1,404,154	182,170	457,113	(886,227)	(1,547,581)	(759,463)	(654,915)	40,016	2,519,424	1,157,210	(2,921,943)
Income tax expense/(benefit)	(2,840,855)	8,406	33,465	14,352	16,754	8,376	2,750	2,750	(19,899)	(59,126)	2,329	1,500	(2,784,632)	30,630	(75,196)
Net income from continuing operations	3,824,968	204,644	896,222	378,222	1,387,400	173,794	454,363	(888,977)	(1,527,682)	(700,337)	(657,244)	38,516	5,304,056	1,126,580	(2,846,747)
Discontinued operations:
Net income from discontinued operations net of income tax expense/(benefit) of $0,$0, $5,280 and ($4,153), respectively	7,469	249,696	4,975	4,975	1,793	254,976	4,975	4,975	(6,018)	172,007	3,475	6,318	267,115	266,719	175,782
Net income from discontinued operations	7,469	249,696	4,975	4,975	1,793	254,976	4,975	4,975	(6,018)	172,007	3,475	6,318	267,115	266,719	175,782
Net income	$ 3,832,437	$ 454,340	$ 901,197	$ 383,197	$ 1,389,193	$ 428,770	$ 459,338	$ (884,002)	$ (1,533,700)	$ (528,330)	$ (653,769)	$ 44,834	$ 5,571,171	$ 1,393,299	$ (2,670,965)
Net income per share from continuing operations - Basic	$ 0.50	$ 0.03	$ 0.12	$ 0.05	$ 0.19	$ 0.02	$ 0.06	$ (0.12)	$ (0.22)	$ (0.10)	$ (0.09)	$ 0.01	$ 0.70	$ 0.15	$ (0.40)
Net income per share from discontinued operations - Basic	0	0.03	0	0	0	0.04	0	0	0	0.02	0	0	0.04	0.04	0.02
Net income per share - Basic	0.50	0.06	0.12	0.05	0.19	0.06	0.06	(0.12)	(0.22)	(0.08)	(0.09)	0.01	0.74	0.19	(0.38)
Net income per share from continuing operations - Diluted	0.46	0.02	0.11	0.05	0.18	0.02	0.06	(0.12)	(0.22)	(0.10)	(0.09)	0.01	0.66	0.15	(0.40)
Net income per share from discontinued operations - Diluted	0	0.03	0	0	0	0.03	0	0	0	0.02	0	0	0.03	0.04	0.02
Net income per share - Diluted	$ 0.46	$ 0.05	$ 0.11	$ 0.05	$ 0.18	$ 0.05	$ 0.06	$ (0.12)	$ (0.22)	$ (0.08)	$ (0.09)	$ 0.01	$ 0.69	$ 0.19	$ (0.38)

Quarterly Results (unaudited)59

Quarterly Results (unaudited) (Details Textual) - USD ($)	3 Months Ended												12 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Discontinued Operation, Tax Effect Of Discontinued Operation	$ (4,153)	$ 5,280	$ 0	$ 0	$ 3,182	$ 0	$ 0	$ 0	$ (3,301)	$ 82,968	$ 0	$ 0	$ 1,127	$ 3,182	$ 79,667
Additional Inventory Reserves	835,000				835,000				835,000				835,000	835,000	835,000
Gross Profit, Total	$ 4,492,799	$ 3,644,438	$ 3,833,833	$ 2,953,232	$ 3,650,785	$ 2,852,879	$ 2,892,650	$ 1,730,254	$ 1,284,929	$ 1,541,158	$ 1,847,266	$ 2,726,626	14,924,302	11,126,568	$ 7,399,979
Fourth Quarter 2013 [Member]
Gross Profit, Total													$ 439,508
Fourth Quarter 2013 [Member] | Minimum [Member]
Gross Profit, Total														$ 439,508

Valuation and Qualifying Acco60

Valuation and Qualifying Accounts (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015		Jun. 30, 2014		Jun. 30, 2013
Allowance for Doubtful Accounts [Member]
Balance at beginning of period	$ 136,868		$ 214,641		$ 155,739
Additions charged to cost and expenses	(10,000)		(39,811)		60,000
Deductions	0		(37,962)	[1]	(1,098)	[1]
Balance at end of period	126,868		136,868		214,641
Inventory Valuation and Obsolescence [Member]
Balance at beginning of period	1,337,586		1,349,526		443,328
Additions charged to cost and expenses	87,041		107,289		916,198
Deductions	(436,856)	[2]	(119,229)	[2]	0
Balance at end of period	$ 987,771		$ 1,337,586		$ 1,349,526
[1]	Reduction in allowance for doubtful accounts due to write off of certain accounts receivable balances.
[2]	Reduction in reserve for obsolescence due to the write off of obsolete items.